|
|Section2= |Section3= }} Rotigaptide (ZP-123) is a drug currently under clinical investigation for the treatment of cardiac arrhythmias – specifically atrial fibrillation. It is a peptide analog that has been shown to increase gap junction intercellular conductance in cardiac muscle cells.〔Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan J, Nattel S (2007). Model- Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. ''Circulation''. 115: 310- 318.〕 Gap junctions are protein channels that are responsible for conducting electrical impulses between cells in the heart to maintain normal rhythm. Gap junction modulation is a promising and novel mechanism of action for the treatment of cardiovascular disorders.〔 Its peptide sequence is Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2. == Indications == Rotigaptide is being studied for its antiarrhythmic effects, specifically for treating atrial fibrillation.〔Guerra J, Everett T, Lee K, Wilson E, Olgin J (2006). Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation. ''Circulation''. 114: 110-118.〕 Atrial fibrillation is an irregular and often rapid heart rhythm. The irregular rhythm, results from abnormal electrical impulses in the heart. The irregularity can be continuous or intermittent. In atrial fibrillation, multiple impulses travel through the atria at the same time. Instead of a coordinated contraction, the atrial contractions are irregular, disorganized and very rapid.〔 These irregular impulses reach the AV node in rapid succession, but not all of them make it past the AV node. Therefore, the ventricles beat slower in an irregular rhythm. The resulting rapid, irregular heartbeat causes an irregular pulse and sometimes a sensation of fluttering in the chest. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Rotigaptide」の詳細全文を読む スポンサード リンク
|